The purpose of this study is to find a recommended dose of LY2940680 that can be safely given
in combination with etoposide and carboplatin followed by LY2940680 alone in participants
with extensive-disease small cell lung cancer. The study will also compare progression-free
survival in participants who are administered etoposide, carboplatin and LY2940680 followed
by LY2940680 alone versus etoposide, carboplatin, and placebo followed by placebo alone.